Genocea Biosciences (GNCA) Stock Price, News & Analysis

Company Overview

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 83,499 shs
• Market Capitalization: $6,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNCA Stock Analysis - Frequently Asked Questions

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.15. The biotechnology company earned $1.64 million during the quarter.

How do I buy shares of Genocea Biosciences?

Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genocea Biosciences investors own include Hawkins (HWKN), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW) and Micron Technology (MU).

Company Calendar

• Last Earnings: 10/27/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNCA
• CUSIP: N/A
• CIK: 1457612
• Web: www.genocea.com
• Phone: (617) 876-8191
• Fax: 617-876-8192
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-33,200,000.00
• Net Margins: N/A
• Pretax Margin: -1,946.15%
• Return on Equity: -182.88%
• Return on Assets: -62.76%

Debt

• Debt-to-Equity Ratio: 0.24
• Current Ratio: 1.35
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: $1.91 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.47 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 58,730,000
• Free Float: 57,788,000
• Market Cap: $6,000.00
• Optionable: Not Optionable
• Beta: 1.61